Coenzyme Q10
Ubiquinone/Ubiquinol
Mitochondrial antioxidant, popular with statin users.
Evidence tier
Moderate
Research weight
Citations
19 verified / 19
Classification
Heart & Metabolic
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Coenzyme Q10?
Coenzyme Q10 (Ubiquinone/Ubiquinol) is a heart and metabolic supplement used for heart failure support. NutriDex grades the human evidence as Moderate. CoQ10 is essential to mitochondrial energy production and acts as a fat-soluble antioxidant. The best evidence is for heart failure, where the Q-SYMBIO trial showed reduced cardiac events. It may modestly ease statin-associated muscle symptoms and reduce migraine frequency. Body levels decline with age and statin use.
Purported Benefits
✓Heart failure support
✓Statin muscle pain
✓Migraine prevention
✓Antioxidant
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Heart failure (mortality & hospitalization)Multiple meta-analyses (32-33 RCTs) show reduced all-cause mortality (RR ~0.64) and HF hospitalization; GRADE moderate, LVEF gains small/inconsistent. | Moderate | ↑ benefit · moderate | 6 |
| Statin-associated muscle symptomsMeta-analyses show reduced muscle pain/weakness vs placebo, but creatine kinase unchanged and authors note evidence remains limited. | Moderate | ↑ benefit · small | 3 |
| Migraine preventionMeta-analysis of 6 RCTs cut monthly attacks (~1.5 fewer) and duration, but not headache severity; small trials. | Moderate | ↑ benefit · small | 3 |
| Blood pressureGRADE dose-response meta-analysis (26 RCTs) lowered systolic BP ~4.8 mmHg, best at 100-200 mg/day in cardiometabolic patients. | Moderate | ↑ benefit · small | 1 |
| Male fertility (sperm parameters)Two 2024-25 meta-analyses improved motility; they disagreed on sperm concentration, so concentration/pregnancy benefit is inconsistent. | Preliminary | ↔ mixed · moderate | 2 |
| Glycemic controlDose-response meta-analysis (40 RCTs) showed tiny changes (HbA1c -0.12%, FG -5.2 mg/dl); statistically real but clinically trivial. | Preliminary | ↑ benefit · negligible | 1 |
| FatigueMeta-analysis (13 RCTs incl. fibromyalgia/CFS) cut fatigue scores (g=-0.40); heterogeneous populations limit confidence. | Preliminary | ↑ benefit · small | 1 |
Dosing & Compounds
Typical Dose
100–300 mg/day with fat for absorption.
Active Compounds
Safety & Cautions
Very safe. Mild GI upset. May reduce warfarin effectiveness. Educational only — always check with your doctor or pharmacist before combining Coenzyme Q10 with any medicine.
Coenzyme Q10 drug interactions
Known or theoretical interactions between Coenzyme Q10 and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Coenzyme Q10 with any medicine.
Monitor
Statins
Statins lower CoQ10 levels; co-use is generally benign (CoQ10 is sometimes taken to offset this).
Statins block the mevalonate pathway shared by CoQ10 synthesis; supplementation replaces it. MSKCC — Coenzyme Q10
Key Studies ★ 19 studies
Meta-analysis
Zhao 2024 (meta-analysis)
✓ PubMed
In a meta-analysis of 32 RCTs (3,763 heart-failure patients), adjunctive CoQ10 reduced all-cause mortality (RR 0.64, 95% CI 0.48-0.85) and HF hospitalization (RR 0.50, 95% CI 0.37-0.67), GRADE moderate.
Systematic review
J Nutr Sci 2025 (systematic review/meta-analysis)
✓ PubMed
Pooling 7 RCTs (389 statin-treated patients), CoQ10 supplementation significantly reduced statin-associated muscle pain intensity (WMD -0.96), though authors note evidence remains limited.
Meta-analysis
Frontiers Pharmacol 2025 (meta-analysis)
✓ PubMed
In 8 RCTs (877 men with idiopathic infertility), CoQ10 improved sperm progressive/total motility and serum testosterone, but did not significantly change sperm concentration or semen volume.
meta-analysis
Ardekani 2023 (NAFLD meta-analysis, Food Sci Nutr)
✓ PubMed
Pooling 6 RCTs of NAFLD patients, CoQ10 supplementation produced an overall non-significant reduction in lipid profiles (TC, LDL, HDL, TG) and liver enzymes (AST, ALT, GGT), though sensitivity ('leave-one-out') analysis showed significant reductions in AST and GGT.
meta-analysis
Liu 2024 (endothelial function meta-analysis, High Blood Press Cardiovasc Prev)
✓ PubMed
Pooling 12 RCTs (489 subjects), CoQ10 supplementation significantly increased flow-mediated dilation (WMD 1.45%, 95% CI 0.55 to 2.36) in a dose-dependent manner, but did not change soluble VCAM or ICAM levels.
umbrella review
Pirro 2023 (inflammation umbrella review)
✓ PubMed
Umbrella review of 7 meta-analyses found CoQ10 (median 200 mg/day for 12 weeks) significantly reduced IL-6 in 4 of 5 and TNF-alpha in 3 of 4 meta-analyses, with CRP significant in only 3 of 7, amid substantial heterogeneity.
Meta-analysis
Zhang 2024
✓ Full text
Meta-analysis of 33 RCTs (search through April 2024) found CoQ10 reduced all-cause mortality (RR 0.64, 95% CI 0.48-0.85, P=0.002) and heart-failure hospitalization (RR 0.50, 95% CI 0.37-0.67, P<0.00001), moderate-quality evidence.
Systematic review
Ubiquinol HF review 2024
✓ PubMed
Systematic review and meta-analysis of 16 studies found ubiquinol/CoQ10 reduced heart-failure-related mortality by 40% and improved exercise capacity, with no significant change in LVEF.
Systematic review
HF overview of reviews 2023
✓ PubMed
Overview of systematic reviews/meta-analyses (search through March 2023) reported CoQ10 increased ejection fraction in 6 of 9 analyses, with absolute LVEF gains of roughly 1.77% to 3.81%.
Meta-analysis
Bakri 2025 (idiopathic male infertility meta-analysis)
✓ PubMed
Systematic review and meta-analysis of 9 RCTs (781 men with idiopathic infertility): CoQ10 significantly improved sperm concentration (MD +10.22 x10^6/mL), total motility (+4.95%), semen volume (+0.17 mL) and seminal CoQ10 levels, and increased clinical pregnancy odds (OR 6.02, 95% CI 1.97-18.41); benefit on morphology was seen with >3 months of treatment, with a favorable safety profile.
Meta-analysis
Zhao 2022 (GRADE dose-response meta-analysis)
✓ PubMed
Across 26 RCTs (1,831 patients with cardiometabolic disorders), CoQ10 lowered systolic blood pressure by 4.77 mmHg (95% CI -6.57 to -2.97), with greatest benefit at 100-200 mg/day.
Meta-analysis
Liang 2022 (GRADE dose-response meta-analysis)
✓ PubMed
Pooling 40 RCTs (2,424 participants), CoQ10 modestly improved glycemic control: fasting glucose -5.22 mg/dl, HbA1c -0.12%, and HOMA-IR -0.69, with 100-200 mg/day most effective.
Meta-analysis
Sazali 2021 (meta-analysis, BMJ Open)
✓ PubMed
Across 6 RCTs (371 adults with migraine), CoQ10 reduced monthly migraine frequency (MD -1.52 attacks) and attack duration, but not headache severity.
meta-analysis
Tsai 2022 (fatigue meta-analysis, Front Pharmacol)
✓ PubMed
Across 13 RCTs (1,126 participants, including fibromyalgia and chronic-fatigue populations), CoQ10 significantly reduced fatigue scores versus placebo (Hedges' g = -0.40, 95% CI -0.64 to -0.16).
Meta-analysis
Qu 2018 (updated meta-analysis)
✓ PubMed
Meta-analysis of 12 RCTs (575 patients) in statin-treated patients: CoQ10 supplementation reduced statin-associated muscle pain (WMD -1.60), weakness (WMD -2.28), cramp (WMD -1.78) and tiredness (WMD -1.75; all p<=0.006) versus placebo, though plasma creatine kinase was unchanged (WMD 0.09, p=0.23).
RCT
CoQ10 HF RCT 2025
✓ Full text
Double-blind RCT of 120 heart-failure patients (CoQ10 2x60 mg/day vs placebo for 6 months) showed significant improvement in global longitudinal strain and NT-proBNP; LVEF rose 38.9% to 40.6% (not statistically significant).
Study
Q-SYMBIO 2014
✓ PubMed
Reduced major cardiovascular events in heart-failure patients.
Study
Skarlovnik 2014
✓ PubMed
Improved statin-associated muscle symptoms in a subset of users.
Study
Sándor 2005
✓ PubMed
Reduced migraine frequency vs placebo.